Comparing the reimbursement of new medicines between Australia and New Zealand
Rajan Ragupathy A and Zaheer-UD-Din Babar B C
+ Author Affiliations
- Author Affiliations
A Waikato Hospital Hamilton, Corner Selwyn and Pembroke Street, Hamilton West, Hamilton, 3204, New Zealand. Email: rajan.ragupathy@gmail.com
B School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Private Mail Bag 92019, Auckland, 1142, New Zealand.
C Corresponding author. Email: z.babar@auckland.ac.nz
Australian Health Review 40(1) 118-119 https://doi.org/10.1071/AH15070
Submitted: 14 April 2015 Accepted: 23 April 2015 Published: 20 July 2015
References
[1] Taylor C, Wonder M. Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand. Aust Health Rev 2015;| Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand.Crossref | GoogleScholarGoogle Scholar | 25751688PubMed |
[2] Aaltonen K, Ragupathy R, Tordoff J, Reith D, Norris P. The impact of pharmaceutical cost containment policies on the range of medicines available and subsidized in Finland and New Zealand. Value Health 2010; 13 148–56.
| The impact of pharmaceutical cost containment policies on the range of medicines available and subsidized in Finland and New Zealand.Crossref | GoogleScholarGoogle Scholar | 19744294PubMed |
[3] Ragupathy MR, Aaltonen K, Tordoff J, Norris P, Reith D. A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand. Pharmacoeconomics 2012; 30 1051–65.
| A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.Crossref | GoogleScholarGoogle Scholar |
[4] Wonder M, Milne R. Access to new medicines in New Zealand compared to Australia. N Z Med J 2011; 124 12–28.
| 22143849PubMed |
[5] Ragupathy R, Kilpatrick K, Babar ZUD. Pharmaceutical pricing in New Zealand. In: Babar Z-U-D, editor. Pharmaceutical Prices in the 21st Century. Basel: Adis/Springer; 2015. pp. 189–208.
[6] Australian Government Department of Health. The Pharmaceutical Benefits Scheme. Setting an approved ex-manufacturer price for new or extended listings. 2015. Available at: http://www.pbs.gov.au/info/industry/pricing/pbs-items/fact-sheet-setting-an-approved-ex-manufacturer-price [verified 31 March 2015].
[7] Australian Government Department of Health. Role of the Pharmaceutical Benefits Advisory Committee. 2015. Available at: http://www.pbac.pbs.gov.au/information/role-of-pbac.html [verified 4 April 2015].
[8] Australian Government Department of Health. Independent review (PBS). 2006. Available at: http://www.independentreviewpbs.gov.au [verified 4 April 2015].
[9] Cumming J, Mays N, Daubé J. How New Zealand has contained expenditure on drugs. BMJ 2010; 340 c2441
| How New Zealand has contained expenditure on drugs.Crossref | GoogleScholarGoogle Scholar | 20483927PubMed |
[10] Duckett S, Breadon P, Ginnivan L, Venkataraman P. Australia’s bad drug deal: high pharmaceutical prices. March 2013. Available at: http://grattan.edu.au/wp-content/uploads/2014/04/Australias_Bad_Drug_Deal_FINAL.pdf [verified 5 May 2015].
[11] Simoens S. Health economic assessment: a methodological primer. Int J Environ Res Public Health 2009; 6 2950–66.
| Health economic assessment: a methodological primer.Crossref | GoogleScholarGoogle Scholar | 20049237PubMed |
[12] Ragupathy R, Menkes DB. Prostate cancer screening and ethical use of limited resources. N Z Med J 2013; 126 92–94.
| 24217598PubMed |
[13] Moodie P, Metcalfe S, Poynton M. Do pharmaceutical score cards give us the answers we seek. N Z Med J 2011; 124 69–74.
| 22143855PubMed |
[14] Lichtenberg FR. The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009. Econ Hum Biol 2014; 13 107–27.
| The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009.Crossref | GoogleScholarGoogle Scholar | 23664114PubMed |
[15] Lee TH, Emanuel EJ. Tier 4 drugs and the fraying of the social compact. N Engl J Med 2008; 359 333–5.
| Tier 4 drugs and the fraying of the social compact.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1cXovFSqtL4%3D&md5=451a1c8b264e27ff0c398fef5c61908dCAS | 18650510PubMed |
[16] Lancet New £50 million cancer fund already intellectually bankrupt. Lancet 2010; 376 389
| New £50 million cancer fund already intellectually bankrupt.Crossref | GoogleScholarGoogle Scholar | 20692511PubMed |
[17] World Health Organization. Health impact assessment: the determinants of Health. 2013. Available at: http://www.who.int/hia/evidence/doh/en/ [verified 5 April 2015].
[18] Organisation for Economic Co-operation and Development (OECD). Health at a glance 2013. 2013. Available at: http://www.oecd.org/els/health-systems/Health-at-a-Glance-2013.pdf [verified 5 April 2015].
[19] Shaw B
[20] New Zealand Ministry of Health. Questions and answers: $5 pharmaceutical co-payments. 2014. Available at: http://www.health.govt.nz/our-work/primary-health-care/primary-health-care-subsidies-and-services/pharmaceutical-co-payments/questions-and-answers-5-pharmaceutical-co-payments [verified 5 April 2015].
[21] Australian Department of Human Services. Pricing of Pharmaceutical Benefits Scheme medicines. 2014. Available at: http://www.humanservices.gov.au/health-professionals/enablers/pricing-of-pbs-medicine [verified 5 April 2015].
